Login to Your Account


QUICK RESPONSE

Cempra Inc. shares rose 28.6 percent on Friday as the company reported that early clinical responses to its oral antibiotic, Taksta, proved noninferior to those for Pfizer Inc.’s oral Zyvox during a phase III trial.

more »


Opinion


Partners in Focus